Materia
Materia Health is an Australian medical technology company developing the MateriaPOD™, a portable preservation platform using active temperature control and proprietary gel technology to safeguard donor organs, tissues, and blood products during transport for healthcare, defence, and veterinary customers.
- Company typePrivate
- Founded2023
- HeadquartersPerth, Australia
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Materia does
Materia Health is an Australian medical technology company headquartered in Perth, Western Australia, developing the MateriaPOD™ — a portable, reusable preservation platform designed to safeguard donor organs, tissues, blood products, and biological specimens during transport. The device replaces century-old ice-based cold storage with active precision temperature control, proprietary gel technology for pressure protection, an integrated rechargeable battery system, high-tech miniaturised packaging, and continuous GPS and temperature monitoring. MateriaPOD is positioned as the first meaningful advancement in organ preservation technology since the 1950s, targeting reductions in primary graft dysfunction (PGD), which affects up to 30% of heart and lung recipients.
The company pursues three vertical markets from a single underlying platform: Healthcare (hospitals, transplant centres, and healthcare systems for organ and tissue transplantation), Defence (military medical services for whole blood preservation in austere environments), and Veterinary (livestock reproduction and artificial insemination). Materia sells directly to enterprise customers through field sales and clinical research partnerships, including a UK NIHR collaboration with the University of Leeds and Leeds Teaching Hospitals NHS Trust established in June 2025 to validate surgical-workflow integration. The company is clinician-led and was founded in response to a patient death following a heart transplant attributed to poor donor organ condition.
Materia is pre-commercial and pre-revenue, operating between prototype and clinical readiness. To date, the company has secured AUD $500,000 in non-dilutive funding via the FHRI Innovation Seed Fund 2024/2025 (October 2024), alongside regional recognition through the WA Innovator of the Year Awards (Rio Tinto Emerging Innovation Award finalist, 2024) and the Freo Start Up Fest Golden Ticket and People's Choice Awards (December 2024). No venture capital rounds, commercial sales, pricing terms, or named customers are disclosed; revenue model is hardware sales with potential consumables/service contracts at commercial stage.
Materia firmographics
Firmographics- Name
- Materia
- Legal name
- Materia Health
- Website
- https://materiahealth.com.au
- Company type
- Private
- Founded year
- 2023
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Materia Health is an Australian medical technology company developing the MateriaPOD™, a portable preservation platform using active temperature control and proprietary gel technology to safeguard donor organs, tissues, and blood products during transport for healthcare, defence, and veterinary customers.
- Ownership category
- akta.pro rank
Materia industry classification
Industry- Product category
- Medical Devices — Organ and Tissue Preservation
- NAICS
- Surgical and Medical Instrument Manufacturing (339112)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Point-of-Care Regenerative Kits & Devices (Processing/Delivery) (HLAMANAK)
Keywords
Where Materia is headquartered
LocationHeadquarters
- HQ city
- Perth
- HQ country
- Australia
- HQ region
- Oceania
Offices1 record
Markets served
Materia business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales
Revenue model
- MateriaPOD Medical Device Sales: Sale of MateriaPOD portable preservation devices to healthcare institutions, defence organisations, and veterinary services. The reusable platform generates recurring revenue through device sales and potential consumables/service contracts.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels4 records
Materia product offering
Product offeringCore offering
Materia Health designs, manufactures, and sells the MateriaPOD™, a portable, reusable preservation platform that uses active precision temperature control, proprietary gel tissue protection, and continuous monitoring to safeguard donor organs, tissues, blood products, and biological specimens during transport. The single integrated platform is adapted for three end markets: healthcare organ/tissue transplantation, defence whole-blood preservation in austere environments, and veterinary livestock reproductive material preservation.
Product overview
Materia Health offers a single unified product platform — the MateriaPOD™ — designed as a breakthrough preservation system for organ and tissue transplantation. The platform provides precise active temperature control, proprietary tissue protection, and continuous monitoring capabilities. The same core platform is adapted across three market segments: Healthcare (organ and tissue transplantation), Defence (whole blood and blood component preservation in austere environments), and Veterinary (reproductive viability and sperm preservation for livestock artificial insemination).
Differentiator
Problem solved
Functional benefit
Products and services
- MateriaPOD™ A portable, reusable preservation platform that uses active precision temperature control, proprietary tissue protection gel technology, and continuous monitoring to safeguard donor organs, tissues, blood products, and biological specimens during transport. It serves hospitals, transplant centres, defence medical services, and veterinary/agricultural organisations by maximising cellular viability and improving transplant, resuscitation, and reproductive outcomes.
Quantifiable outcome
- Reduces primary graft dysfunction (PGD) incidence, affecting up to 30% of heart and lung recipients
- +3 more outcomes
Companies that use Materia
Customer profileSegments3 records
Ideal customer profiles3 records
Materia technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
Materia partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core and minor.
- University of LeedscoreCollaboration through the National Institute for Health and Care Research (NIHR) HealthTech Research Centre in Accelerated Surgical Care to integrate MateriaPOD into surgical workflows and investigate preservation and transport of biological materials in the UK healthcare setting.
- Leeds Teaching Hospitals NHS TrustcorePartnership with the NHS trust to validate MateriaPOD platform performance and gather clinical insights to guide device design and accelerate development in surgical environments.
- UK in AustraliaminorUK in Australia facilitated the London Tech Week attendance opportunity awarded through Freo Start Up Fest awards, supporting international market expansion.
Scale indicators2 records
Recent moves5 records
Expansion highlights5 records
Materia competitors and assessment
Company assessmentBroad incumbents
- Terumo: Japan-based large medical device company with significant blood banking, blood component storage, and transfusion portfolio (Terumo BCT). Broad incumbent adjacent to Materia's defence and veterinary blood preservation use cases.
- Haemonetics: US-based publicly-traded blood management company offering whole blood and blood component collection, processing, and storage technology. Adjacent incumbent to Materia's defence blood product preservation use case, with broader blood management portfolio.
Direct peers
- OrganOx: UK-based company commercialising normothermic machine perfusion (metra) for liver and kidney preservation. Direct competitor in clinical organ preservation, addressing the same transplant medicine market that MateriaPOD targets.
- IMV Technologies: France-based company specialising in animal reproduction technology, including artificial insemination equipment and cryopreservation tools for livestock. Comparable to Materia's veterinary sperm-preservation use case for AI breeding.
- XVIVO Perfusion: Sweden-based publicly-traded company developing organ preservation technologies including Kidney Assist, XPS for lung preservation, and other perfusion systems. Direct competitor across multiple organ preservation indications.
- Minitube: Germany-based company specialising in animal reproduction technology including AI, embryo transfer, and cryopreservation. Comparable to Materia's livestock sperm-preservation use case for artificial insemination.
- TransMedics: US-based publicly-traded company whose Organ Care System (OCS) preserves and transports donor hearts, lungs, and livers in a perfused state. Direct competitor in organ preservation and transport for transplantation, with established FDA approval and commercial deployment.
- Paragonix Technologies: US-based company developing portable organ preservation and transport devices (SherpaPak and related product lines) for heart, lung, kidney, and liver. MateriaPOD's portable preservation platform with active temperature control is most directly comparable to Paragonix's portable cold-chain product portfolio.
- Bridge to Life: US-based company providing Belzer UW solution and other static cold-storage organ preservation products. Competes in the same organ preservation market that MateriaPOD targets, though with established chemical solutions rather than active temperature control.
- Preservation Solutions: US-based company focused on kidney preservation and the LifePort platform. Competes in the organ preservation space with static cold-storage-focused approaches analogous to the traditional cold chain MateriaPOD aims to upgrade.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks5 records
Key highlights6 records
Customer concentration
Materia social profiles
Digital presenceMateria financial estimates
Financial estimateRevenue estimate
Valuation estimate
Materia leadership team
Management profileNumber of profiles
Materia funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Materia M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Materia
What does Materia do?
Materia Health designs, manufactures, and sells the MateriaPOD™, a portable, reusable preservation platform that uses active precision temperature control, proprietary gel tissue protection, and continuous monitoring to safeguard donor organs, tissues, blood products, and biological specimens during transport. The single integrated platform is adapted for three end markets: healthcare organ/tissue transplantation, defence whole-blood preservation in austere environments, and veterinary livestock reproductive material preservation.
Is Materia a public or private company?
Materia is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Materia founded?
Materia was founded in 2023. It employs 1 to 10 people.
Where is Materia based?
Materia is headquartered in Perth, Australia, in the Oceania region.
How does Materia make money?
One revenue line is on record: materiaPOD Medical Device Sales.
Who are Materia's main competitors?
Broad incumbents on record are Terumo and Haemonetics. Direct peers are OrganOx, IMV Technologies, XVIVO Perfusion, Minitube, TransMedics, Paragonix Technologies, Bridge to Life and Preservation Solutions.
Does Materia have an API?
No public API is recorded for Materia.
What industry is Materia in?
Materia's product category is Medical Devices — Organ and Tissue Preservation. Its primary akta.pro industry code is HLAMANAK, Point-of-Care Regenerative Kits & Devices (Processing/Delivery). Its NAICS code is 339112 and its SIC code is 3841.